Switching From Risperidone Long Acting Injection (Consta) to Paliperidone Palmitate (Sustenna) in Patients With Schizophrenia and Its Influence on Subjective Well-Being: A Prospective Observational Study

Trial Profile

Switching From Risperidone Long Acting Injection (Consta) to Paliperidone Palmitate (Sustenna) in Patients With Schizophrenia and Its Influence on Subjective Well-Being: A Prospective Observational Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Dec 2015

At a glance

  • Drugs Paliperidone (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Dec 2015 Status changed from recruiting to completedas reported by ClinicalTrials.gov.
    • 12 Apr 2013 Planned End Date changed from 1 Dec 2012 to 1 Sep 2014 as reported by ClinicalTrials.gov.
    • 16 Oct 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top